26,221 Shares in Qiagen N.V. $QGEN Bought by Waterfront Wealth Inc.

Waterfront Wealth Inc. acquired a new stake in Qiagen N.V. (NYSE:QGEN) during the 1st quarter, Holdings Channel reports. The fund acquired 26,221 shares of the company’s stock, valued at approximately $1,050,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Boston Partners acquired a new position in Qiagen during the third quarter worth about $179,450,000. Norges Bank acquired a new stake in shares of Qiagen in the 4th quarter valued at approximately $166,500,000. Dimensional Fund Advisors LP acquired a new stake in shares of Qiagen in the 3rd quarter valued at approximately $58,079,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Qiagen by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after purchasing an additional 906,589 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Qiagen by 9.7% during the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock valued at $355,614,000 after purchasing an additional 697,342 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Zacks Research upgraded shares of Qiagen from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 29th. Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th. Robert W. Baird set a $43.00 target price on shares of Qiagen and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Stifel Nicolaus set a $36.00 price target on shares of Qiagen and gave the stock a “hold” rating in a report on Monday, May 18th. Finally, Citigroup reiterated a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $43.15.

Qiagen Trading Down 1.1%

Shares of NYSE:QGEN traded down $0.47 during midday trading on Friday, hitting $41.52. 3,565,122 shares of the stock were exchanged, compared to its average volume of 2,901,811. The business’s 50-day moving average price is $36.59 and its 200 day moving average price is $42.60. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. The stock has a market capitalization of $8.56 billion, a price-to-earnings ratio of 21.68, a P/E/G ratio of 4.19 and a beta of 0.64.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.54. The business had revenue of $492.32 million during the quarter, compared to analyst estimates of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. During the same quarter last year, the business earned $0.56 EPS. Analysts predict that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th will be paid a dividend of $0.35 per share. The ex-dividend date of this dividend is Tuesday, July 7th. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 90.0%. Qiagen’s payout ratio is 18.32%.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.